These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27182968)

  • 1. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.
    McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP
    Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern.
    Kim HN; Woo HY; DO SI; Kim HS
    In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.
    Anglesio MS; O'Neill CJ; Senz J; Gilks CB; McCluggage WG
    Histopathology; 2017 Dec; 71(6):1014-1017. PubMed ID: 28746984
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
    Auer K; Bachmayr-Heyda A; Aust S; Grunt TW; Pils D
    Cancer Lett; 2017 Mar; 388():158-166. PubMed ID: 27940126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
    Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
    Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma].
    Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F
    Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    Ritterhouse LL; Nowak JA; Strickland KC; Garcia EP; Jia Y; Lindeman NI; Macconaill LE; Konstantinopoulos PA; Matulonis UA; Liu J; Berkowitz RS; Nucci MR; Crum CP; Sholl LM; Howitt BE
    Mod Pathol; 2016 Aug; 29(8):893-903. PubMed ID: 27150160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease.
    Kupryjanczyk J; Thor AD; Beauchamp R; Poremba C; Scully RE; Yandell DW
    Mod Pathol; 1996 Mar; 9(3):166-73. PubMed ID: 8685209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are all pelvic (nonuterine) serous carcinomas of tubal origin?
    Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R
    Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
    Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
    Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
    Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP
    Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.
    Yamamoto Y; Ning G; Howitt BE; Mehra K; Wu L; Wang X; Hong Y; Kern F; Wei TS; Zhang T; Nagarajan N; Basuli D; Torti S; Brewer M; Choolani M; McKeon F; Crum CP; Xian W
    J Pathol; 2016 Mar; 238(4):519-530. PubMed ID: 26415052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
    Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
    Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
    [No Abstract]   [Full Text] [Related]  

  • 20. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
    J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.